Pacira Pharmaceuticals diskutieren
Pacira Pharmaceuticals
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Aktie / Pharmazeutika / Small Cap /
16,40 €
-4,65 %
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Truist Financial Co. from $45.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $42.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Raymond James from $41.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock, down previously from $45.00.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Needham & Company LLC from $22.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at HC Wainwright from $57.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at HC Wainwright from $48.00 to $65.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $32.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at Truist Financial Corporation from a "hold" rating to a "buy" rating. They now have a $30.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for PCRX provided by MarketBeat
Neueste Beiträge
DA_Davidson in Pdf Solutions diskutieren